NEWBRY — Newbury Pharmaceuticals AB Income Statement
0.000.00%
Last trade - 00:00- SEK63.83m
- SEK57.42m
- SEK10.27m
Annual income statement for Newbury Pharmaceuticals AB, fiscal year end - August 31st, SEK millions except per share, conversion factor applied.
2021 August 31st | 2022 August 31st | 2023 August 31st | |
|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS |
| Standards: | SAS | SAS | SAS |
| Status: | Final | Final | Final |
| Revenue | |||
| Total Revenue | 2.83 | 5.52 | 10.3 |
| Cost of Revenue | |||
| Gross Profit | 0.46 | 1.56 | 3.95 |
| Selling / General / Administrative Expenses | |||
| Depreciation and Amortization | |||
| Other Operating Expenses | |||
| Total Operating Expenses | 8.45 | 20.2 | 29.9 |
| Operating Profit | -5.62 | -14.7 | -19.6 |
| Total Net Non Operating Interest Income / Expense | |||
| Net Income Before Taxes | -5.56 | -14.7 | -19.4 |
| Provision for Income Taxes | |||
| Net Income After Taxes | -5.56 | -14.7 | -19.4 |
| Net Income Before Extraordinary Items | |||
| Net Income | -5.56 | -14.7 | -19.4 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||
| Income Available to Common Shareholders Including Extraordinary Items | |||
| Diluted Net Income | -5.56 | -14.7 | -19.4 |
| Diluted Weighted Average Shares | |||
| Basic EPS Including Extraordinary Items | |||
| Diluted EPS Including Extraordinary Items | |||
| Diluted EPS Excluding Extraordinary Items | |||
| Normalised Income Before Taxes | |||
| Normalised Income After Taxes | |||
| Normalised Income Available to Common Shareholders | |||
| Diluted Normalised EPS | -0.253 | -0.751 | -0.995 |